For example, the drug crizotinib approved to
treat ALK - positive lung cancer, showed a PFS of 10.9 months.
Not exact matches
The FDA has approved several
ALK inhibitors for
treating non-small cell lung cancer.
Among patients with non-small cell lung cancer (NSCLC) fueled by
ALK gene alterations who were being
treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the
ALK gene over the first two months of treatment was associated with increased progression - free survival.
The NIH and Mass General are at the vanguard of a major effort to identify and
treat cancer based on causative gene mutations like the one found in
ALK.
Several prospective studies show a brain metastasis prevalence of 40 % to 70 % in patients previously
treated with
ALK inhibitors.
A and B, two
ALK + ALCL cell lines, Karpas 299 and SU - DHL1, were
treated with the selective PI3K inhibitor, LY294002, at a concentration of 0, 5, 10, or 20 μg / μL.